Casa
checkmate pt br

CheckMate914

Por um escritor misterioso

Descrição
CheckMate914
CheckMate 914: Adjuvant nivolumab–ipilimumab not supported for high-risk RCC
CheckMate914
New Perioperative Strategies Emerge for High-Risk, Resectable RCC
CheckMate914
Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro
CheckMate914
Toni Choueiri, MD on X: Checkmate-914 (adjuvant nivo/ipi) vs placebo in high-risk Kidney Cancer is out in the @TheLancet: the study is negative with no DFS/OS advantage. 33% disc. for toxicity could
CheckMate914
CheckMate914
CheckMate914
ESMO22: CheckMate 914-studie naar adjuvant nivo+ipi bij RCC behaalt primaire uitkomstmaat niet - Oncologie
CheckMate914
Strengthening Our Grip on Immuno-Oncology in Genitourinary Cancers: Understanding Science Through Stories
CheckMate914
Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
CheckMate914
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
CheckMate914
IJMS, Free Full-Text
CheckMate914
EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse
CheckMate914
Toni Choueiri, MD on X: Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC
CheckMate914
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
CheckMate914
Cancers, Free Full-Text
CheckMate914
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized Renal Cell Carcinoma at High Risk of Relapse After Nephrectomy: Results From the Randomized, Phase 3 CheckMate 914 Trial
de por adulto (o preço varia de acordo com o tamanho do grupo)